30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Integra LifeSciences Posts 4Q17, 2017 Revenue -

ORTHOWORLD estimates Integra LifeSciences’ (IART) 4Q17 orthopaedic revenue at US $27.42MM, +7.3% from 4Q16, and 2017 revenue of $107.8MM, +8.6% vs. 2016.

Estimated segment sales and growth follow.

  4Q17  4Q16  $ Change  % Change 
 Joint Recon Extremities $5.8  $5.0  $0.7  14.5% 
 Trauma $21.7  $20.5  $1.1  5.6% 
Total  $27.4  $25.6  $1.9  7.3% 


  2017  2016  $ Change  % Change 
 Joint Recon Extremities $22.6  $19.5  $3.1  15.9% 
 Trauma $85.1  $79.7  $5.4  6.8% 
Total  $107.8  $99.2  $8.5  8.6% 

Total ankle and shoulder reconstruction portfolios continue to drive IART’s orthopaedic growth, with both growing in double-digits separately and at 25% together, with ankle growing faster than shoulder. The Cadence total ankle launch is experiencing strong momentum both inside and outside of the U.S. Lower extremities, excluding total ankles, were down about -5% in 4Q.

In 2H17, IART implanted the first Cadence ankle as part of a non-randomized, prospective, multi-center postmarket study in the U.S., Canada and Europe. The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.

The creation of dedicated sales channels for ortho is underway, and is expected to support stronger performance in 2H18.

Sources: Integra LifeSciences, ORTHOWORLD estimates

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.